

Promentis Pharmaceuticals focuses on developing antipsychotic drugs to treat schizophrenia. Among its major competitors, Promentis Pharmaceuticals is ranked in 8th place for NPS while Alexza Pharmaceuticals is 1st, and Biogen is 2nd.Their current valuation is $95.00M